Hengrui Pharma (600276.SH) announced that its independently developed biosimilar, Shudi Insulin Injection, has received marketing approval from the National Medical Products Administration. This is the first domestically developed long-acting insulin analogue in China, indicated for treating adult type 2 diabetes. The company has invested approximately 544.3 million yuan (unaudited) in the project. China, with 148 million diabetes patients, is the world's largest diabetes market, and over 90% of these patients have type 2 diabetes.

Beijing Junzheng (300223.SZ) reported that Deputy General Manager and Board Secretary Zhang Min completed a share reduction plan from May 27 to June 30, selling 236,000 shares at an average price of 233 yuan per share, representing 0.05% of total shares. After the reduction, Zhang Min holds 1.11 million shares, or 0.23% of total equity.

Tianzhihang (688277.SH) plans to acquire 62% equity of Shanghai Orthopedics through a share issuance, which is expected to constitute a major asset restructuring. The company's stock will resume trading on July 30, 2026. The target company, specializing in knee and hip joint implants, has its core subsidiaries and production base in the U.S., with mature overseas sales networks in Europe and Japan. The acquisition aims to supplement Hengrui's orthopedics implant product line and accelerate the overseas expansion of its surgical robot products.

Huajin Chemical (000059.SZ) disclosed that its Deputy General Manager Yan Zenghui has been placed under investigation and留置 measures by a supervisory authority. The company stated that production and operations are normal and unaffected.

Buybacks & Shareholding Changes

Guangdian Electric (601616.SH) plans to repurchase shares worth 100 million to 200 million yuan.

Hongsoft Technology (688088.SH) announced that its actual controller proposed a share repurchase of 100 million to 150 million yuan.

Huawu Co., Ltd. (300095.SZ) received a commitment letter from Industrial and Commercial Bank of China for a stock repurchase loan of up to 72 million yuan.

Huakai Yibai (300592.SZ) said its chairman proposed a share repurchase of 30 million to 50 million yuan.

Zhongke Tongda (688038.SH) announced that shareholder Guanggu Growth plans to reduce its stake by up to 3%.

Kehua Holdings (603161.SH) reported that shareholder Zhang Yu reduced his holdings by 1.9 million shares from July 24 to 28.

Major Contracts

China State Construction (601668.SH) recently secured major projects totaling 13.39 billion yuan.

Yitian Intelligent (300911.SZ) announced that its subsidiary signed a contract for computing power resource services worth 1.11 billion yuan.

Other News

Lanyu Co., Ltd. (001322.SZ) received a warning letter for violating fundraising rules, but the company has completed rectification.